AR016128A1 - Una composicion farmaceutica que comprende un inhibidor de recaptacion de serotonina y un beta-bloqueante y el empleo de la misma para la produccion de unmedicamento. - Google Patents

Una composicion farmaceutica que comprende un inhibidor de recaptacion de serotonina y un beta-bloqueante y el empleo de la misma para la produccion de unmedicamento.

Info

Publication number
AR016128A1
AR016128A1 ARP980103371A ARP980103371A AR016128A1 AR 016128 A1 AR016128 A1 AR 016128A1 AR P980103371 A ARP980103371 A AR P980103371A AR P980103371 A ARP980103371 A AR P980103371A AR 016128 A1 AR016128 A1 AR 016128A1
Authority
AR
Argentina
Prior art keywords
same
beta
pharmaceutical composition
production
acronym
Prior art date
Application number
ARP980103371A
Other languages
English (en)
Spanish (es)
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of AR016128A1 publication Critical patent/AR016128A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
ARP980103371A 1997-07-11 1998-07-10 Una composicion farmaceutica que comprende un inhibidor de recaptacion de serotonina y un beta-bloqueante y el empleo de la misma para la produccion de unmedicamento. AR016128A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9714675.7A GB9714675D0 (en) 1997-07-11 1997-07-11 Novel composition

Publications (1)

Publication Number Publication Date
AR016128A1 true AR016128A1 (es) 2001-06-20

Family

ID=10815744

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980103371A AR016128A1 (es) 1997-07-11 1998-07-10 Una composicion farmaceutica que comprende un inhibidor de recaptacion de serotonina y un beta-bloqueante y el empleo de la misma para la produccion de unmedicamento.

Country Status (26)

Country Link
EP (1) EP0996466A2 (id)
JP (1) JP2002508003A (id)
KR (1) KR20010021644A (id)
CN (1) CN1262627A (id)
AP (1) AP2000001728A0 (id)
AR (1) AR016128A1 (id)
AU (1) AU9340198A (id)
BG (1) BG104119A (id)
BR (1) BR9810996A (id)
CA (1) CA2295822A1 (id)
CO (1) CO4950552A1 (id)
DZ (1) DZ2556A1 (id)
EA (1) EA200000112A1 (id)
GB (1) GB9714675D0 (id)
HU (1) HUP0003074A3 (id)
ID (1) ID24191A (id)
IL (1) IL133869A0 (id)
MA (1) MA24604A1 (id)
NO (1) NO20000107D0 (id)
OA (1) OA11276A (id)
PE (1) PE99699A1 (id)
PL (1) PL338017A1 (id)
SK (1) SK72000A3 (id)
TR (1) TR200000074T2 (id)
WO (1) WO1999002142A2 (id)
ZA (1) ZA986138B (id)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE457169T1 (de) 1998-10-15 2010-02-15 Imp Innovations Ltd Verbindungen für die behandlung von gewichtsverlust
CA2348871C (en) 1998-11-02 2009-04-14 John G. Devane Multiparticulate modified release composition
ATE526950T1 (de) 1999-10-29 2011-10-15 Euro Celtique Sa Hydrocodon-formulierungen mit gesteuerter freisetzung
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
GB0004003D0 (en) * 2000-02-22 2000-04-12 Knoll Ag Therapeutic agents
EP2283829A1 (en) 2000-10-30 2011-02-16 Euro-Celtique S.A. Controlled release hydrocodone formulations
EP1793818A2 (en) * 2004-09-17 2007-06-13 Neurocure Ltd. Pindolol for treating premenstrual syndrome and premenstrual dysphoric disorder
CN100469356C (zh) * 2006-09-08 2009-03-18 山东益康药业有限公司 复方阿替洛尔缓释片及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2732335C2 (de) * 1976-07-27 1983-01-20 Sandoz-Patent-GmbH, 7850 Lörrach Tablette zur enteralen Verabreichung von Indolyloxyalkanolamin-Derivaten
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
WO1997006792A1 (en) * 1995-08-16 1997-02-27 Eli Lilly And Company Potentiation of serotonin response
EP0792649A1 (en) * 1996-02-29 1997-09-03 Eli Lilly And Company Treatment of sleep disorders

Also Published As

Publication number Publication date
PL338017A1 (en) 2000-09-25
PE99699A1 (es) 1999-12-21
DZ2556A1 (fr) 2003-02-15
NO20000107L (no) 2000-01-10
EP0996466A2 (en) 2000-05-03
WO1999002142A3 (en) 1999-04-15
EA200000112A1 (ru) 2000-10-30
CA2295822A1 (en) 1999-01-21
CO4950552A1 (es) 2000-09-01
HUP0003074A3 (en) 2001-12-28
ID24191A (id) 2000-07-13
TR200000074T2 (tr) 2000-05-22
MA24604A1 (fr) 1999-04-01
IL133869A0 (en) 2001-04-30
OA11276A (en) 2003-07-31
SK72000A3 (en) 2000-12-11
AP2000001728A0 (en) 2000-03-31
BG104119A (en) 2000-12-29
HUP0003074A2 (hu) 2001-01-29
ZA986138B (en) 2000-01-10
NO20000107D0 (no) 2000-01-10
KR20010021644A (ko) 2001-03-15
BR9810996A (pt) 2000-08-08
AU9340198A (en) 1999-02-08
GB9714675D0 (en) 1997-09-17
WO1999002142A2 (en) 1999-01-21
JP2002508003A (ja) 2002-03-12
CN1262627A (zh) 2000-08-09

Similar Documents

Publication Publication Date Title
BRPI0407993B8 (pt) compostos inibidores de p38 e composições farmacêuticas compreendendo os mesmos
ECSP056148A (es) Compuestos inmunosupresores y composiciones
RS20120158A3 (en) Phenyl-piperazine Derivatives As Serotonin Resorption Inhibitors
NO20060402L (no) 3-amino choman og 2-aminotetralinderivater
WO2007050783A3 (en) Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
UY28041A1 (es) Metodos de dosis bajas para el tratamiento de trastornos en los cuales la actividad del tnfa es perjudicial.
NO20052683D0 (no) Nye pyridopyrimidinonforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
DK1626720T3 (da) 4-(2-Phenylsulfanyl-phenyl)-piperidinderivater som serotonin-genoptagelseshæmmer
NO20070124L (no) Nye disubstituerte fenylpiperidiner/piperaziner som modulatorer av dopamin neurotransmisjon
AR035782A1 (es) Amidas sustituidas de acido benzofuran-2-carboxilico, un procedimiento para su preparacion, las preparaciones farmaceuticas que las contienen y el uso de las mismas para preparar un medicamento
CO4950552A1 (es) Nueva composicion lectivos de la reabsorcion de seotonina y un bloqueador b
NO20070914L (no) Fremgangsmater for behandling av nervesystemforstyrrelser og tilstander
NZ336587A (en) Spray dried paroxetine compositions using organic solvent selected from pyridine, acetic acid, acetonitrile, acetone, ethanol, propan-1-ol or tetrahydrofuran
DK1383756T3 (da) Cumarinderivater til anvendelse som antikoagulanter
IL165840A0 (en) Combination therapy wherein a serotonin reuptake inhibitor is used
NO20055206L (no) 4-(2-fenyloksyfenyl)-piperidin eller -1,2,3,6-tetrahydropyridinderivater som serotonin-reopptaksinhibitorer
DE60201590D1 (de) Antidepressiv wirksame azaheterocyclymethyl-derivative von oxaheterocycyl-anellierten (1,4)-benzodioxanen
IS2425B (is) Nýjar heteróarýlafleiður, framleiðsla þeirra og notkun
Zhan et al. Design, synthesis, biological evaluation, and molecular docking of novel benzopyran and phenylpyrazole derivatives as Akt inhibitors
ATE304016T1 (de) Antidepressive (sssri) azaheterocyclylmethylderivate von 7,8-dihydro-3h- 6,9-dioxa-1,3-diazacyclopenta (a) naphthalin
NZ506893A (en) Paroxetine compositions adsorbed or absorbed by a solid carrier
ATE334989T1 (de) Antidepressive azaheterocyclylmethyl-derivate von 2,3-dihydro-1,4-dioxino 2,3-föchinoxalin
EA200501579A1 (ru) Производные 4-(2-фенилсульфанилфенил)-1,2,3,6-тетрагидропиридина в качестве ингибиторов повторного поглощения серотонина
BR0115276A (pt) Composições farmacêuticas, uso de pelo menos um dos compostos, compostos, e, processo para a preparação de uma composição farmacêutica
NO20021198D0 (no) Nye isoindoloindolonforbindelser, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdende dem